Sofia Bruera graduated from the honors program at Southern Methodist University with a Bachelor of Arts in Psychology and a Bachelor of Arts in French in 2006. She attended University of Houston Law School where she was the business development editor of the Houston Journal of Health Law & Policy. During law school, she received a publication award for an article written for the journal. Sofia was licensed to practice law in Texas in 2009. She is fluent in Spanish and French.
Since 2009, the majority of Sofiaâ€™s work has been focused on pharmaceutical and medical device litigation. Sofia has worked on a variety of Multi-District Litigations including:
Digitek Products Liability MDL No. 1968; Fosamax Products Liability MDL. No. 1789; Seroquel Products Liability MDL No. 1769; Chinese Drywall MDL No. 2047; Denture Cream MDL No. 2051; Vioxx Products Liability MDL No. 1657; DePuy ASR Hip Implant Litigation MDL No. 2197; DePuy Pinnacle Hip Implant Litigation MDL No. 2244; Mirena IUD MDL No. 2434, CR Bard Pelvic Mesh MDL No. 2187; Ethicon Pelvic Mesh MDL No, 2327; Boston Scientific Pelvic Mesh MDL No. 2326; and American Medical Systems Pelvic Mesh MDL No. 2325. In addition to MDL experience, Sofia has worked on a variety of state court pharmaceutical and medical device cases. These cases include the Paxil birth defect litigation and PPH cases against the diet drug manufacturer Herbalife, in which she drafted motions, presented Plaintiffs and took depositions. Additionally, Sofia worked on several Fentanyl patch cases in which she handled depositions and motions including a pivotal response to a Motion for Writ of Prohibition before the West Virginia Supreme Court. The Court issued a seminal ruling in that case permitting Fentanyl patch cases to proceed in West Virginia where the Defendant was located.
Most recently, Sofia has worked on a litigation involving the drug Tysabri. Tysabri causes a fatal brain virus known as progressive multifocal leukoencephalopathy (â€œPMLâ€). Sofia has handled every aspect of these cases. The cases have been filed in courts across the country including California, New Jersey, New York, Utah and Massachusetts. Given the number of cases, she moved for the first consolidation of these cases in the country in Massachusetts State Court. She recently received a favorable result on a forum non conveniens issue before the Massachusetts Appeals Court on one of her cases.
Sofia is licensed in Texas and is currently admitted to practice in the following courts:
Massachusetts Superior Court; United States District Court of Massachusetts; Northern District of California; United States District Court of Utah; United States District Court of New Jersey; Northern District of New York; Southern District of New York; Pennsylvania Court of Common Pleas; and Texas State Courts. Given her experience in pharmaceutical and medical device cases, Sofia has presented and published on various topics. This includes the AAJ Topamax Teleseminar and the articles:
â€œRegulation of Internet Pharmacies using RFID tags, 2D barcodes and Biometricsâ€ in the Houston Journal of Health Law & Policy; â€œThe 510k Fast Track and Medical Device Discoveryâ€ in Trial Magazine,â€ â€œThe Off-Label Promotion Conundrumâ€ in the AAJ Products Liability Newsletter; â€œWhere are the Women? Tips for Increasing Female Leadership in Mass Tortsâ€ in the AAJ Women Trial Lawyerâ€™s Newsletter; â€œThe Power of Gender Equityâ€ in Trial Magazine; â€œUpdate on Learned Intermediary in Medical Device Casesâ€ in the AAJ Products Liability Newsletter; â€œInsurance Company Denial of Payment and Enforced Changes in the Type and Dose of Opioid Analgesics for Patients with Cancer Painâ€ in Palliative & Supportive Care Journal; and â€œEmerging Litigation: Controversy over Power Morcellatorsâ€ in Trial Talk Magazine December/January 2015 and â€œRemand in Maritime Casesâ€ Admiralty Law Newsletter, Winter 2015. Texas Monthly Magazine named Sofia a Rising Star from 2014-2017. Sofia has also been named one of the top 100 National Trial Lawyers and top 100 Mass Tort lawyers for 2017.